Novel capsaicin cough endpoints effectively discriminate between healthy controls and patients with refractory chronic cough

4Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Rationale: Chronic cough is a common problem, substantially affecting quality of life. Effective treatments and diagnostic clinical tools for refractory chronic cough are lacking which remains a diagnosis of exclusion. Objectives: To investigate capsaicin evoked cough responses in healthy volunteers and refractory chronic cough patients and assess the discriminatory ability of novel endpoints. Methods: Dose-response capsaicin cough challenges were performed, and receiver operating characteristic curves constructed to evaluate the discriminatory value of novel endpoints; Emax (maximum number of coughs evoked by any capsaicin concentration) and ED50 (capsaicin concentration evoking at least half of Emax). Measurements and main results: Ninety-three healthy volunteers (median age 39yrs(IQR; 29–52), 47 females) and 51 refractory chronic cough patients (59yrs(53–67), 31 females) were studied. Emax was significantly higher in the patient group compared to healthy volunteers (p < 0.001) and ED50 was significantly lower (p = 0.001). Both parameters were influenced by gender; females had a higher Emax (p = 0.009) and more sensitive ED50 (p < 0.001) but there were no correlations with other patient demographics. There was a significant relationship between Emax and cough frequency in the patient group (p < 0.001). Emax effectively discriminated between the groups (AUC = 0.83, 95% CI; 0.75–0.90, p < 0.001) independently of ED50 which was less favourable (AUC = 0.66, 95% CI; 0.57–0.76, p = 0.002). Emax and ED50 were shown to be repeatable, and the dose-response method well tolerated. Conclusion: Novel capsaicin dose-response endpoints effectively discriminate between healthy controls and refractory chronic cough patients, which may better represent pathophysiological mechanisms and show promise for development as a tool to identify patients with cough hyper-excitability. Clinical trial registration: www.isrctn.com; ISRCTN23684347.

Cite

CITATION STYLE

APA

Holt, K. J., Belcher, J., & Smith, J. A. (2023). Novel capsaicin cough endpoints effectively discriminate between healthy controls and patients with refractory chronic cough. Respiratory Medicine, 208. https://doi.org/10.1016/j.rmed.2023.107142

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free